TAHO Pharma begins patient dosing in US phase III trial of antithrombotic oral dissolving film, TAH3311: Taipei Wednesday, November 20, 2024, 16:00 Hrs [IST] TAHO Pharmaceuticals ...

TAHO Pharmaceuticals Ltd. announced the dosing of the first subjects in its U.S. Phase III clinical trial for its lead product, TAH3311, an innovative antithrombotic oral dissolving film (ODF). In ...

In the ever-evolving world of pharmaceutical development, the quest to innovate and improve the delivery of drug substances remains a top priority. Among the many formulation strategies, oral liquid ...

Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second Subject ...

A WORRYING amount of Brits are developing mouth cancer, with a new report warning of record-breaking cases. Some 10,825 ...